Advertisement

Topics

[Comment] New perspectives for TAS-102: TASK successful?

19:09 EDT 29 Jul 2017 | The Lancet

The US Food and Drug Administration and European Medicines Agency have granted approval to TAS-102 for the treatment of refractory metastatic colorectal cancer.1,2 In The Lancet Oncology, Yasutoshi Kuboki and colleagues report on the results of C-TASK FORCE,3 a phase 1/2 study on the combination of TAS-102 with bevacizumab. The rationale for this study was sound and strong. Phosphorylated trifluridine concentration and tumour growth inhibition are increased with the combination of TAS-102 and bevacizumab compared with either drug alone.

Original Article: [Comment] New perspectives for TAS-102: TASK successful?

NEXT ARTICLE

More From BioPortfolio on "[Comment] New perspectives for TAS-102: TASK successful?"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...